BIHi005-A
General
Donor Information
General Donor Information |
|
Sex | male |
Age of donor (at collection) | 25-29 |
Ethnicity | asian |
Phenotype and Disease related information (Donor) |
|
Diseases | No disease was diagnosed.
|
Disease associated phenotypes | no phenotypes |
Family history | Mutation in the LMNA gene in other family members but not in this sample frame shift mutation in the LMNA gene that leads to the early termination of translation (c. 349_350insG; p. K117fs) |
Karyotyping (Donor) |
|
Has the donor karyotype been analysed? |
Yes
Karyotyping method:
Molecular karyotyping by SNP array
http:// |
Other Genotyping (Donor) |
|
Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
Other cell lines of this donor | |
All cell lines of this donor's relatives |
Has brother:
|
External Databases (Donor) |
|
BioSamples | SAMEA104012190 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
Please provide contact information of the holder of the original Donor Information Sheet. | liqunzhu@stanford.edu |
Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
Is there other documentation provided to the donor for consenting purposes? | No |
Confirm that consent was obtained by a qualified professional | Yes |
Has the donor agreed to be re-contacted? | Unknown |
Has the donor been informed about how her/his data will be protected? | Yes |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Does consent expressly prevent the derivation of pluripotent stem cells? | No |
Does consent pertain to a specific research project? | No |
Does consent permit unforeseen future research, without further consent? | Yes |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
an academic institution? | Yes |
a public organisation? | Yes |
Does consent expressly permit collection of genetic information? | Yes |
Does consent expressly permit storage of genetic information? | Yes |
Does consent prevent dissemination of genetic information? | No |
How may genetic information associated with the cell line be accessed? | Controlled Access |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | No |
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | David Spiegel, M.D., Administrative Panel on Human Subjects in Medical Research Stanford University |
Approval number | 350 (Panel: 3) |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
Name of accrediting authority involved? | David Spiegel, M.D., Administrative Panel on Human Subjects in Medical Research Stanford University |
Approval number | 350 (Panel: 3) |
Do you have obligations to third parties in regard to the use of the cell line? | No |
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
Is there an MTA available for the cell line? | Yes |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | Miltenyi mRNA reprogramming |
hIPSC Derivation
General |
|
Source cell type |
Any skin fibroblast that is part of some dermis.
|
Source cell origin |
Any portion of the organ that covers that body and consists of a layer of epidermis and a layer of dermis.
Synonyms
|
Age of donor (at collection) | 25-29 |
Collected in | 2012 |
Reprogramming method |
|
Vector type | Non-integrating |
Vector | mRNA Miltenyi |
Is reprogramming vector detectable? |
No |
Methods used |
Immunostaining
|
Vector free reprogramming |
|
Other |
|
Derived under xeno-free conditions |
No |
Derived under GMP? |
No |
Available as clinical grade? |
No |
Culture Conditions
Surface coating | Matrigel/Geltrex |
Feeder cells |
No |
Passage method |
Enzyme-free cell dissociation
EDTA
|
O2 Concentration | 5 % |
CO2 Concentration | 5 % |
Medium |
Essential 8™
|
Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
POU5F1 (OCT-4) |
Yes |
|
||||
SOX2 |
Yes |
|
||||
SSEA-4 |
Yes |
|||||
TRA 1-60 |
Yes |
|
Differentiation Potency
In vitro directed differentiation
In vitro directed differentiation
Marker | Expressed |
platelet derived growth factor receptor beta |
Yes |
cadherin 5 |
Yes |
TnnT2 |
Unknown |
Microbiology / Virus Screening |
|
HIV 1 | Negative |
Hepatitis B | Negative |
Hepatitis C | Negative |
Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.